Polly Verification Report for Clinical Trial

Polly Verified : V1.0

Dataset Information

This report has been verified by Polly as per framework version 1.0 Learn More

Clinical Trial Summary

Curation Summary Statistics

Stat Label Stat Value
Total Drug Molecules 3
AUC Values 21
Numerical Values 48
Treatment Arms 16
Primary Route Oral

Clinical Trial and Patent Summary

Studies Table

nct_id title official_title status study_type phase start_date completion_date conditions
NCT03107988 NANT 2015-02: A Phase 1 Study of Lorlatinib Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma COMPLETED INTERVENTIONAL PHASE1 2017-09-05 2025-01-31 Neuroblastoma
NCT03009292 Pharmacokinetic Study of Lenvatinib Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor COMPLETED INTERVENTIONAL PHASE1 2018-08-06 2021-08-27 Solid Tumor
NCT03220295 Putative Cognitive Enhancer VU319 Study of the M1 Positive Allosteric Modulator VU0467319 COMPLETED INTERVENTIONAL PHASE1 2017-07-28 2019-10-30 Cognitive Impairment

Patent Table

id docs patent_number patent_title filing_date grant_date assignee abstract nct_id
1 Lorlatinib US11299500B2 CRYSTALLINE FORM OF LORLATINIB FREE BASE HYDRATE Oct. 4, 2018 Apr. 12, 2022 Pfizer Inc., New York, NY (US) This invention relates to a crystalline form of lorlatinib free base hydrate and pharmaceutical compositions for treating abnormal cell growth such as cancer. NCT03107988
8 Lenvatinib US9006256B2 ANTITUMOR AGENT FOR THYROID CANCER Apr. 8, 2011 Apr. 14, 2015 Eisai R&D Management Co., Ltd., Tokyo (JP) Pharmaceutical compositions and therapeutic methods for treating thyroid carcinoma using RET kinase inhibiting substances. NCT03009292

Data Integrity Validations

Validation Check Description Status
Dose/AUC Linkage Ensures every dose amount has a corresponding AUC exposure value. Passed
Curated Compound IDs Ensures all compounds have pubchem_cid as the unique identifier. Passed
Curated Treatment Arm Ensures all studies have detailed treatment arm defined. Passed
Treatment Arm To PK values Check PK Parameters and AUC row tables mapped to treatment arm. Passed
Tmax Median Check Tmax is reported as a Mean instead of a Median (standard practice is median/range). Passed
Unit Normalization Validation of unit conversion to standardized ng*h/ml or µg*h/ml for AUC and μg/mL or ng/ml for Cmax. Passed
Schema Adherence Check for presence of Primary and Foreign keys in each table (e.g., compounds has pubchem_cid, nct_id). Passed
Linkage Adherence Check that there are no orphan Primary or Foreign Keys. Passed
Data Duplicates Check that there are no duplicated NCT IDs, Patent IDs, and Treatment Arm IDs. Passed
Data Logic Check that Start Dates < Completion Dates. Passed
Human Verified Literature and unstructured data extraction is human verified and updated. Passed
Download Sample Dataset